Literature DB >> 24240028

Study of the stability of packaging and storage conditions of human mesenchymal stem cell for intra-arterial clinical application in patient with critical limb ischemia.

Patricia Gálvez-Martín1, Abdelkrim Hmadcha2, Bernat Soria2, Ana C Calpena-Campmany3, Beatriz Clares-Naveros4.   

Abstract

Critical limb ischemia (CLI) is associated with significant morbidity and mortality. In this study, we developed and characterized an intra-arterial cell suspension containing human mesenchymal stem cells (hMSCs) for the treatment of CLI. Equally, the stability of cells was studied in order to evaluate the optimal conditions of storage that guarantee the viability from cell processing to the administration phase. Effects of various factors, including excipients, storage temperature and time were evaluated to analyze the survival of hMSCs in the finished medicinal product. The viability of hMSCs in different packaging media was studied for 60 h at 4 °C. The best medium to maintain hMSCs viability was then selected to test storage conditions (4, 8, 25 and 37 °C; 60 h). The results showed that at 4 °C the viability was maintained above 80% for 48 h, at 8 °C decreased slightly, whereas at room temperature and 37 °C decreased drastically. Its biocompatibility was assessed by cell morphology and cell viability assays. During stability study, the stored cells did not show any change in their phenotypic or genotypic characteristics and physicochemical properties remained constant, the ability to differentiate into adipocytes and osteocytes and sterility requirements were also unaltered. Finally, our paper proposes a packing media composed of albumin 20%, glucose 5% and Ringer's lactate at a concentration of 1×10(6) cells/mL, which must be stored at 4 °C as the most suitable to maintain cell viability (>80%) and without altering their characteristics for more than 48 h.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adipose mesenchymal stem cell; Critical limb ischemia; Injectable; Intra-arterial; Packaging; Storage

Mesh:

Year:  2013        PMID: 24240028     DOI: 10.1016/j.ejpb.2013.11.002

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  11 in total

1.  Enhancing effect of glucose microspheres in the viability of human mesenchymal stem cell suspensions for clinical administration.

Authors:  Patricia Gálvez; Maria J Martín; Ana C Calpena; Juan A Tamayo; Maria A Ruiz; Beatriz Clares
Journal:  Pharm Res       Date:  2014-06-25       Impact factor: 4.200

2.  Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?

Authors:  Guido Moll; Jessica J Alm; Lindsay C Davies; Lena von Bahr; Nina Heldring; Lillemor Stenbeck-Funke; Osama A Hamad; Robin Hinsch; Lech Ignatowicz; Matthew Locke; Helena Lönnies; John D Lambris; Yuji Teramura; Kristina Nilsson-Ekdahl; Bo Nilsson; Katarina Le Blanc
Journal:  Stem Cells       Date:  2014-09       Impact factor: 6.277

3.  Alginate-Encapsulation for the Improved Hypothermic Preservation of Human Adipose-Derived Stem Cells.

Authors:  Stephen Swioklo; Andrei Constantinescu; Che J Connon
Journal:  Stem Cells Transl Med       Date:  2016-01-29       Impact factor: 6.940

Review 4.  Mesenchymal Stem Cells as a Prospective Therapy for the Diabetic Foot.

Authors:  Qinan Wu; Bing Chen; Ziwen Liang
Journal:  Stem Cells Int       Date:  2016-10-27       Impact factor: 5.443

5.  Preservation media, durations and cell concentrations of short-term storage affect key features of human adipose-derived mesenchymal stem cells for therapeutic application.

Authors:  Fengli Zhang; Huaijuan Ren; Xiaohu Shao; Chao Zhuang; Yantian Chen; Nianmin Qi
Journal:  PeerJ       Date:  2017-05-17       Impact factor: 2.984

6.  Cryopreserved mesenchymal stem cells regain functional potency following a 24-h acclimation period.

Authors:  Ben Antebi; Amber M Asher; Luis A Rodriguez; Robbie K Moore; Arezoo Mohammadipoor; Leopoldo C Cancio
Journal:  J Transl Med       Date:  2019-08-29       Impact factor: 5.531

7.  Effects of carrier solutions on the viability and efficacy of canine adipose-derived mesenchymal stem cells.

Authors:  Tania Sultana; Ahmed Abdal Dayem; Soo Bin Lee; Ssang-Goo Cho; Jeong Ik Lee
Journal:  BMC Vet Res       Date:  2022-01-07       Impact factor: 2.741

8.  Proline-based solution maintains cell viability and stemness of canine adipose-derived mesenchymal stem cells after hypothermic storage.

Authors:  Pongsatorn Horcharoensuk; Sunantha Yang-En; Amarin Narkwichean; Ruttachuk Rungsiwiwut
Journal:  PLoS One       Date:  2022-03-01       Impact factor: 3.240

9.  Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products.

Authors:  Clémentine Mirabel; Eduard Puente-Massaguer; Anna Del Mazo-Barbara; Blanca Reyes; Philip Morton; Francesc Gòdia; Joaquim Vives
Journal:  J Transl Med       Date:  2018-10-24       Impact factor: 5.531

Review 10.  Principal Criteria for Evaluating the Quality, Safety and Efficacy of hMSC-Based Products in Clinical Practice: Current Approaches and Challenges.

Authors:  Juan Antonio Guadix; Javier López-Beas; Beatriz Clares; José Luis Soriano-Ruiz; José Luis Zugaza; Patricia Gálvez-Martín
Journal:  Pharmaceutics       Date:  2019-10-24       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.